COVID-19: Zydus Cadila gets DGCI nod for phase 3 clinical trials with biological therapy

The company had completed the phase 2 clinical trials with PegiHep last month. In a regulatory filing, Zydus Cadila said it has received approval from the DCGI to start the phase 3 clinical trials in COVID-19 patients with its biological therapy Pegylated Interferon alpha-2b or PegiHep.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3lFhqzJ
via IFTTT